Primers: Combining Radiotherapy and Immunotherapy using next genertaion radiotherapy biomaterials
引物:使用下一代放射治疗生物材料结合放射治疗和免疫治疗
基本信息
- 批准号:9302964
- 负责人:
- 金额:$ 22.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-25 至 2019-03-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAntigensAwardBiocompatible MaterialsBiodistributionC57BL/6 MouseCD8-Positive T-LymphocytesCancer PatientCancer VaccinesCellsCessation of lifeCustomCytotoxic T-LymphocytesDendritic CellsDevelopmentDiseaseDistantDoseElectronsEnsureEnzyme-Linked Immunosorbent AssayExposure toFluorescenceFrightGoalsGoldGrantGranulocyte-Macrophage Colony-Stimulating FactorImmuneImmune responseImmune systemImmunologic AdjuvantsImmunologic MemoryImmunotherapyImplantIn SituIn VitroInfiltrationIrradiated tumorLungMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of pancreasMalignant neoplasm of prostateMeasuresMediatingMemoryMetastatic Prostate CancerMethodsMusNeoplasm MetastasisNewly DiagnosedNormal tissue morphologyOutcomePancreasPatient-Focused OutcomesPatientsPolymersPre-Clinical ModelPublic HealthQuality of lifeRadiationRadiation OncologistRadiation therapyRadiation-Sensitizing AgentsRadioresistanceRecruitment ActivityResourcesRiskScheduleSiteSurvival RateT cell differentiationT cell responseTNFRSF5 geneTechnologyTestingTimeTissuesToxic effectTreatment EfficacyTumor AntigensTumor Cell LineUnited States National Institutes of HealthVaccinesWeightWorkX-Ray Computed Tomographybiodegradable polymercancer recurrencecell killingcohortcontrolled releasedesignfightinghigh rewardin vivoinnovationkillingslung metastaticlymph nodesmouse modelnanoparticleneoplastic cellnovel strategiespreventradioresistantradiosensitizingresponsesubcutaneoustreatment responsetumoruptake
项目摘要
Project Summary
Metastasis accounts for over 90% of all cancer associated suffering and death, and arguably
presents the most formidable challenges in cancer management. The central innovation and
overall goal of this project is the development of new design radiotherapy biomaterials that
could be employed to significantly boost pancreatic/lung/prostate cancer cure rate: including
treatment of metastasis and overcoming radioresistance, all at no additional inconvenience to
patients. The new biomaterials are designed to simply replace the inert biomaterials
(fiducials/spacers), which are currently routinely implanted to ensure spatial accuracy during
radiotherapy. These new biomaterials specifically incorporate a payload of non-toxic targeted
radiosensitizing gold nanoparticles (GNP), and immunoadjuvants in a biodegradable polymer
matrix. Once in place, the new design biomaterials controllably release the payload directly into
the tumor as the polymer degrades. During radiotherapy, the released GNP will significantly
enhance local tumor cell kill, substantially boosting dose to radioresistant tumor cells via
Einstein’s photoelectric effect, with minimal toxicity to healthy tissue. Meanwhile, antigens from
irradiated tumor cells work with the released immunoadjuvant to prime a robust T cell response,
which may kill metastatic cells distant from the irradiated site (abscopal effect) and establish
immune memory to prevent cancer recurrence. Slow in-situ release of the payload will minimize
systemic/overlapping toxicities, which are currently a critical barrier/concern with competing
approaches. Overall, our low risk, potential high-reward innovation could significantly enhance
survival and quality of life for pancreatic/ung/prostate cancer patients.
项目摘要
转移占所有相关痛苦和死亡的所有癌症的90%以上,而Arguaby
提出了癌症管理中最大的挑战。
该项目的总体目标是开发新设计放疗生物材料
可以用来显着提高胰腺/肺/前列腺癌治疗率:包括
对转移和克服放射线的治疗,这一切都没有给您带来任何不便。
患者设计的新生物材料旨在取代Imateritrs
(基准/垫片),目前通常会植入以确保空间精度
放射疗法。
可生物降解聚合物中的放射敏金纳米颗粒(GNP)和免疫辅助
矩阵一次。
作为聚合物的肿瘤降解。
增强局部肿瘤细胞杀伤,通过
爱因斯坦的光电效应,最小的毒效应至健康组织
辐照的肿瘤细胞与释放的免疫辅助剂一起工作,以促进稳健的T细胞反应,
这可能杀死远离辐照部位的转移细胞(脱离脱离的位置)
免疫记忆以防止癌症复发。
系统性/重叠的毒性,目前是竞争的关键障碍/关注
总体而言,我们的低风险,潜在的高回报创新可以大大提高
胰腺/UNG/前列腺癌患者的生存和生活质量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Wilfred Ngwa其他文献
Wilfred Ngwa的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Wilfred Ngwa', 18)}}的其他基金
Liquid Immunogenic Fiducial Eluter (LIFE) for Cervical Cancer Treatment
用于宫颈癌治疗的液体免疫原性基准洗脱器 (LIFE)
- 批准号:
10385213 - 财政年份:2022
- 资助金额:
$ 22.92万 - 项目类别:
Radio-immunotherapy dose-painting (RAID) treatment for hormonal resistant prostate cancer
放射免疫治疗剂量涂抹 (RAID) 治疗激素抵抗性前列腺癌
- 批准号:
10484689 - 财政年份:2022
- 资助金额:
$ 22.92万 - 项目类别:
Biomaterial Drones for Image-Guided Drug Delivery during radiotherapy
用于放射治疗期间图像引导药物输送的生物材料无人机
- 批准号:
10335157 - 财政年份:2021
- 资助金额:
$ 22.92万 - 项目类别:
Biomaterial Drones for Image-Guided Drug Delivery during radiotherapy
用于放射治疗期间图像引导药物输送的生物材料无人机
- 批准号:
10627008 - 财政年份:2021
- 资助金额:
$ 22.92万 - 项目类别:
Biomaterial Drones for Image-Guided Drug Delivery during radiotherapy
用于放射治疗期间图像引导药物输送的生物材料无人机
- 批准号:
10404865 - 财政年份:2021
- 资助金额:
$ 22.92万 - 项目类别:
Biomaterial Drones for Image-Guided Drug Delivery during radiotherapy
用于放射治疗期间图像引导药物输送的生物材料无人机
- 批准号:
10594527 - 财政年份:2021
- 资助金额:
$ 22.92万 - 项目类别:
Brachytherapy in situ dose-painting administered via gold-nanoparticle eluters
通过金纳米颗粒洗脱器进行近距离放射治疗原位剂量涂抹
- 批准号:
8737015 - 财政年份:2013
- 资助金额:
$ 22.92万 - 项目类别:
Brachytherapy in situ dose-painting administered via gold-nanoparticle eluters
通过金纳米颗粒洗脱器进行近距离放射治疗原位剂量涂抹
- 批准号:
9326917 - 财政年份:2013
- 资助金额:
$ 22.92万 - 项目类别:
Brachytherapy in situ dose-painting administered via gold-nanoparticle eluters
通过金纳米颗粒洗脱器进行近距离放射治疗原位剂量涂抹
- 批准号:
8912431 - 财政年份:2013
- 资助金额:
$ 22.92万 - 项目类别:
Brachytherapy in situ dose-painting administered via gold-nanoparticle eluters
通过金纳米颗粒洗脱器进行近距离放射治疗原位剂量涂抹
- 批准号:
8581475 - 财政年份:2013
- 资助金额:
$ 22.92万 - 项目类别:
相似国自然基金
E3泛素连接酶MDM2对乙肝表面抗原组装和分泌的影响及机制研究
- 批准号:82300690
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
EGCG联合焦磷酸钠修饰小清蛋白抗原表位的降敏机理研究
- 批准号:22368024
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
乙肝病毒特异性受体NTCP的抗原识别结构基础和别构抑制剂筛选
- 批准号:32301001
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于蛋白特征序列模式广泛鉴定人基因组HERV元件env内源性超抗原的研究
- 批准号:32370663
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
牙鲆腹腔源MHCII和CD80/86阳性外泌体对抗原特异性免疫应答调控机制的研究
- 批准号:32373160
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 22.92万 - 项目类别:
Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Acute Disseminated Encephalomyelitis (ADEM)
开发一种新型核苷挽救途径靶向小分子抑制剂来治疗急性播散性脑脊髓炎 (ADEM)
- 批准号:
10755864 - 财政年份:2023
- 资助金额:
$ 22.92万 - 项目类别:
Feasibility, Acceptability, and Pilot Testing of a Behavioral Intervention for Chronic Migraine
慢性偏头痛行为干预的可行性、可接受性和试点测试
- 批准号:
10494152 - 财政年份:2021
- 资助金额:
$ 22.92万 - 项目类别:
Feasibility, Acceptability, and Pilot Testing of a Behavioral Intervention for Chronic Migraine
慢性偏头痛行为干预的可行性、可接受性和试点测试
- 批准号:
10708137 - 财政年份:2021
- 资助金额:
$ 22.92万 - 项目类别:
Feasibility, Acceptability, and Pilot Testing of a Behavioral Intervention for Chronic Migraine
慢性偏头痛行为干预的可行性、可接受性和试点测试
- 批准号:
10351573 - 财政年份:2021
- 资助金额:
$ 22.92万 - 项目类别: